Lymphoma

Latest News

Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma
Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma

December 11th 2025

The FDA has given a PDUFA date of April 8, 2026, to the nivolumab/AVD regimen for stage III or IV classical Hodgkin lymphoma.

Disease Progression Noted After Epcoritamab/Glofitamab in R/R LBCL
Disease Progression Noted After Epcoritamab/Glofitamab in R/R LBCL

December 11th 2025

Prior bendamustine exposure correlated with worse complete response rates with axi-cel among those with relapsed/refractory follicular lymphoma.
Axi-cel Produces Enduring Real-World Responses in R/R Follicular Lymphoma

December 9th 2025

The 3-year event-free survival was 88.9% and 30.0% in patients with high-risk LBCL who did and did not achieve a CR at 6 months, respectively.
Axi-Cel Yields Boosted Survival in Patients With High-Risk LBCL and 6-Month CR

December 9th 2025

Data showed no significant differences in the incidence of CRS and ICANS with the use prophylactic dexamethasone in a retrospective review.
High-Grade ICANS Severity Decreases Via Dexamethasone After Axi-Cel in LBCL

December 9th 2025

Latest CME Events & Activities

More News

Site Logo

Study Identifies Clinical Factors That Predict Outcome in Aggressive Non-Hodgkin's Lymphoma

James O. Armitage, MD
April 1st 1995

Today, we can cure a significant portion of people with aggressive non-Hodgkin's lymphomas. The cure rate at 5 years for all patients with advanced diffuse large-cell lymphoma is approximately 35%.

Site Logo

Acute Lymphocytic Leukemia

Jorge E. Cortes, MD;Hagop M. Kantarjian, MD
April 1st 1995

Acute lymphocytic leukemia (ALL) is a malignant disorder resulting from the clonal proliferation of lymphoid precursors with arrested maturation [1]. The disease can originate in lymphoid cells of different lineages, thus giving rise to B- or T-cell leukemias or sometimes mixed-lineage leukemia.

<1
...
596061626364>